Perspective Therapeutics, Inc.

For the period ended Dec 31, 2025. Filed Mar 16, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 16, 2026

CATX$0.86+1.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(In thousands, except shares and par value data)

	December 31,	December 31,
	2025	2024
ASSETS
Current assets:
Cash and cash equivalents	$30,629	$61,580
Short-term investments	114,108	165,336
Accounts receivable, net of allowance for doubtful accounts: $375 and $543	6	116
Prepaid expenses and other current assets	3,646	4,128
Total current assets	148,389	231,160
Noncurrent assets:
Property and equipment, net	76,597	57,321
Right-of-use asset, net	1,500	2,215
Intangible assets, in-process research and development	40,000	50,000
Other assets, net	486	405
Total assets	$266,972	$341,101
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable and accrued expenses	$20,511	$10,343
Lease liability	623	957
Accrued personnel expenses	7,489	5,478
Note payable	56	52
Deferred Income (Note 3)	-	1,400
Total current liabilities	28,679	18,230
Noncurrent liabilities:
Lease liability, net of current portion	1,005	1,428
Note payable, net of current portion	1,569	1,625
Deferred Income, net of current portion (Note 3)	26,600	26,600
Deferred tax liability	1,702	2,495
Other noncurrent liabilities	386	55
Total liabilities	59,941	50,433
Commitments and contingencies (Note 16)
Stockholders’ equity:
Preferred stock: $0.001 par value; 7,000,000 shares authorized; 5,000,000 designated Series B convertible; no shares issued	-	-
Common stock: $0.001 par value; authorized 750,000,000 shares; issued 74,337,990 and 70,671,464 shares	74	70
Additional paid-in capital	541,687	522,368
Accumulated other comprehensive income (loss)	110	(51)
Accumulated deficit	(334,840)	(231,719)
Total stockholders’ equity	207,031	290,668
Total liabilities and stockholders’ equity	$266,972	$341,101

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.